Colon cancer metastasis blocked by curcumin
the ONA take:
According to new research published in the journal PLOS One, curcumin, a bioactive molecule derived from tumeric, can prevent colon cancer metastasis. Researchers from the University of Arizona's Steele Children's Research Center in Tucson, Arizona, curcumin inhibits cortacin, a protein necessary for cell movement, in colon cancer. Because cortacin is often overexpressed in cancer cells, it provides cancer cells with the ability to move and metastasize to other parts of the body.
The researchers discovered the active part of cortacin, Phospho Tyrosine 421 (pTyr421) to be overexpressed in malignant colon cancer cells. The malignant cancer cells were then treated with curcumin and found that curcumin inhibited pTyr421. Tus, the colon cancer cells lost their ability to spread and migrate.
This study lays the foundation for future studies involving curcumin to be conducted for the prevention of cancer metastasis. Eventually, drugs may be designed with curcumin to block colon cancer cells from spreading.
According to the Centers for Disease Control and Prevention (CDC), colorectal cancer is the second leading cause of cancer-related death of both men and women in the United States.
Curcumin, derived from the spice turmeric, blocks the protein cortactin in colon cancer.
Novel research led by the UA Steele Children's Research Center has identified one of the mechanisms by which curcumin, a bioactive molecule derived from the spice turmeric, can prevent cancer cell metastasis in colon cancer.
A team of researchers led by the University of Arizona's Steele Children's Research Center discovered that curcumin – the bioactive molecule derived from the spice turmeric – blocks the protein cortactin in colon cancer.
Cortactin, a protein essential for cell movement, frequently is overexpressed in cancer, thus facilitating cancer cell metastasis to other organs in the body.
Sign Up for Free e-newsletters
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer
- Better Postoperative Outcomes With RAMIE for Esophageal Cancer
- Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|